Israeli medical technology company Inspira Technologies has secured an additional patent approval for its Vortx orbiting blood oxygenation delivery system in the US.
Vortx is the core technology of the company’s advanced Inspira Art device.
The technology that aims to oxygenate blood without fibre membranes would potentially transform the medical field, by reducing both blood damage and costs.
The current US patent approval brings the total of claims deemed novel for the core technology of the Inspira Art device, to 32.
Inspira Technologies CEO Dagi Ben-Noon said: “We view this as another major leap forward in blood oxygenation technologies, representing another crucial milestone highlighting the core technological capabilities of the Inspira Art.”
According to the company, current fibre technologies for blood oxygenation significantly harm the patient’s blood cells, as they force blood to flow through multiple fibre layers.
The high resistance to blood flow can severely damage blood components, causing hemolysis, white blood cell damage, inflammatory and immune system activation, and blood clotting.
Inspira said that its Inspira Art device is designed to support the 20 million intensive care unit patients with respiratory failure each year, who mostly depend on mechanical ventilators.
Also, Inspira Art provides a potential alternative by maintaining stable oxygen saturation levels without the need for ventilators while patients can remain awake during treatment.
Earlier this year, the Inspira ART100 system received the US Food and Drug Administration (FDA) 510(k) approval for use in Cardiopulmonary Bypass procedures.
In addition, the system secured the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.
Inspira’s other products, including the Inspira Art500 or Gen 2, the Inspira Cardi-ART portable modular device and the HYLA blood sensor, are currently under development.
